Cytek BioSciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $206.7M+3.1% YoYTTM through 30 Jun 2026
Net Income -$80.6MTTM through 30 Jun 2026
Free Cash Flow -$12.1MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 51.8% |
| EBITDA Margin | -17.9% |
| Operating Margin | -20.1% |
| Net Margin | -39.0% |
Returns
-19.5%ROE
-14.4%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio5.04x
Net Debt-$261Mnet cash position
Cash & Equivalents$73.8M
Quality Metrics
Altman Z-Score4.07
Piotroski F-Score3 / 9
FCF Margin-5.8%
Rule of 40-4.8
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $201.5M
Diluted EPSFY2025: $-0.52
Dividend
No dividend
Capital Allocation
R&D Spend$37.3M
Capex Intensity2.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Product | $144.2M | -6.0% | View detailsProduct revenue declined due to global macroeconomic pressures and spending pullbacks by major pharmaceutical companies. |
| Service and Reagents (Recurring) | $57.3M | +21.0% | View detailsManagement expects continued growth in high-margin recurring revenue lines to drive long-term profitability. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.